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from the study because of abnormal colposcopy without biopsy, no visualised transformation zone, and thus no biopsy or representative biopsy. Thus, a total of 1,785 women (462 in group A and 1,323 in group B) were included in the study.
Study design
The study was a prospective diagnostic cohort study that was undertaken in both public and private clinics in France. In the study, conventional Pap smears, LBC, colposcopy and biopsies were all conducted at the same time. All samples were treated within one month of sampling. There was no loss to follow-up.
Analysis of effectiveness
All of the patients included in the study were accounted for in the analysis. The outcome used in the analysis was the sensitivity and specificity of each of the three diagnostic tests under investigation in comparison with the gold standard. Each sample was read twice: the first was a clinical reading, each Pap smear and LBC was read in each laboratory by two different pathologists; the second was optimised reading of anonymous slides without clinical data. In cases of disagreement, a consensus diagnosis was organised on a multiple view microscope. An independent expert was sought only if consensus could not be reached.
Effectiveness results
For lesions of Grade CIN-1 (cervical intraepithelial neoplasia) or higher in the high-risk population (group A), the sensitivity and specificity of each test were as follows:
Pap smear optimised reading, 92% (range: 90 to 94) and 80% (range: 75 to 85), respectively; LBC optimised reading, 90% (range: 87 to 92) and 76% (range: 71 to 81), respectively; HC II using HR-HPV, 79% (range: 74 to 83) and 77% (range: 71 to 83), respectively; and LBC in combination with HC II using HR-HPV, 85% (range: 80 to 89) and 82% (range: 76 to 88), respectively.
For lesions of Grade CIN-1 or higher in the screening population (group B), the sensitivity and specificity of each test were as follows:
Pap smear optimised reading, 74% (range: 66 to 83) and 91% (range: 90 to 93), respectively; LBC optimised reading, 73% (range: 65 to 82) and 90% (range: 89 to 92), respectively; HC II using HR-HPV, 64% (range: 53 to 76) and 86% (range: 85 to 88), respectively; and LBC in combination with HC II using HR-HPV, 67% (range: 56 to 78) and 94% (range: 92 to 95), respectively.
For lesions of grade CIN-II or higher in the high-risk population (group A), the sensitivity and specificity of each test were as follows:
Pap smear optimised reading, 85% (range: 81 to 89) and 92% (range: 89 to 94), respectively; LBC optimised reading, 78% (range: 73 to 83) and 94% (range: 92 to 96), respectively; HC II using HR-HPV, 80% (range: 74 to 86) and 54% (range: 49 to 60), respectively; and LBC in combination with HC II using HR-HPV, 80% (range: 74 to 86) and 93% (range: 90 to 96), respectively.
For lesions of grade CIN-II or higher in the screening population (group B), the sensitivity and specificity of each test were as follows:
Pap smear optimised reading, 60% (range: 45 to 75) and 99% (range: 99 to 99), respectively; LBC optimised reading, 65% (range: 50 to 80) and 98% (range: 98 to 99), respectively; HC II using HR-HPV, 96% (range: 88 to 100) and 85% (range: 83 to 87), respectively; and LBC in combination with HC II using HR-HPV, 76% (range: 59 to 93) and 97% (range: 97 to 98), respectively.
Clinical conclusions
The authors concluded that, compared with conventional Pap smears, LBC and HPV tests do not appear to improve the effectiveness of cervical cancer screening.
Measure of benefits used in the economic analysis
The authors did not derive a measure of health benefit. In effect, a cost-consequences analysis was performed.
Direct costs
The perspective adopted in the economic analysis was not explicitly reported, but it appears to have been that of the provider of the screening tests. The costing study evaluated the production costs of the conventional smear test, LBC and the HPV test in a private laboratory receiving over 100,000 smear tests per year. The same process was observed in a public-based hospital laboratory. The costs included in the analysis were for staff, tasks, equipment and consumables necessary for each screening technique.
Another costing study was performed in which an optimised production process was defined. This allowed the evaluation of the costs to be independent from the specificities of the observation sites, and to correspond to the maximal production capacities in view of the technical capacities of the equipment involved and the French work legislation.
The third costing estimated the cost of each of the physical quantities of materials and consumables and the salaries associated with each task.
The final study looked at the effects of variations in the annual number of examinations on the process and the costs.
The authors did not report the life expectancy of the equipment used. If the equipment used had a life span of over 2 years, the authors would ideally have had to convert these costs into net present value (i.e. discount the costs of the equipment over its lifespan). It was unclear if the authors did this. The cost results were presented in a figure. The price year was 2002.
Statistical analysis of costs
The costs were treated as point estimates (i.e. the data were deterministic).
Indirect Costs
The indirect costs were not included.
Currency
US dollars ($). The authors used the $ to Euro exchange rate for 2002.
Sensitivity analysis
The authors did not perform any sensitivity analysis.
